Publications

Phage Foundry member names are bolded.

2026

  1. Patel J, Swartz SE, Oromi-Bosch A, Yong L, LaTurner ZW, Demaray JE, Voelker A, Ono R, Vu P, Rao P, Luskin H, Andrade P, Cui ML, Mchedlishvili G, Hayes MM, Aluwihare N, Iglesias-Aguirre CE, MacKenzie EC, Rodriguez CI, Devkota S, Diamond S, Cress BF. Bridge recombinase enables versatile rewriting of bacterial genomes. bioRxiv 2026:2026.04.29.721476. https://doi.org/10.64898/2026.04.29.721476
  2. González-Delgado A, Bonillo-Lopez L, Johnson MS, Knödlseder N, Ko C-C, Lekbach Y, Oh J-H, Selvakumar H, Wold MC, Yu Z, Aragón V, Gralnick JA, Güell M, Hatfull GF, Keitz BK, Koskella B, Mutalik VK, van Pijkeren J-P, Shipman SL. Genome editing of phylogenetically distinct bacteria using cross-species retron-mediated recombineering. Nat Biotechnol 2026:1–13. https://doi.org/10.1038/s41587-026-03076-6.
  3. [Preprint] Moriniere L, Noonan AJC, Kazakov A, Pena M, Svab M, Rivera-Lopez EO, Maucourt F, Johnson MS, Roux S, Koskella B, Deutschbauer AM, Dudley EG, Mutalik VK, Arkin AP. Enabling the prediction of phage receptor specificity from genome data. bioRxiv 2026:2026.04.02.716166. https://doi.org/10.64898/2026.04.02.716166.
  4. Mutalik VK, Inman JL, Chang H, Arkin A, Mao J-H. Phage therapy in oncology: opportunities for cancer prevention and treatment. Trends Mol Med 2026;0. https://doi.org/10.1016/j.molmed.2026.02.001.
  5. [Preprint] Trinh J, Mutalik VK, Mageeney CM. Discovery, induction, and screening of prophages in clinical Acinetobacter baumannii isolates. bioRxiv 2026:2026.02.16.706188. https://doi.org/10.64898/2026.02.16.706188.

2025

2024

Relevant Reading from 2023 and Earlier